Treatment of pemphigus with rituximab / 中国医学科学院学报
Acta Academiae Medicinae Sinicae
; (6): 107-110, 2009.
Article
in Zh
| WPRIM
| ID: wpr-259062
Responsible library:
WPRO
ABSTRACT
Pemphigus is a life-threatening autoimmune blistering disease affecting the skin and mucosa. Patients with severe pemphigus require long-term treatment with corticosteroids and other immunosuppressive drugs, which can lead to serious adverse events. Rituximab, a monoclonal antibody directed against the CD20 antigen of B lymphocytes, has been demonstrated to be effective in recalcitrant and life-threatening pemphigus.
Full text:
1
Index:
WPRIM
Main subject:
Therapeutics
/
Pemphigus
/
Antigens, CD20
/
Therapeutic Uses
/
Allergy and Immunology
/
Antibodies, Monoclonal, Murine-Derived
/
Rituximab
Limits:
Humans
Language:
Zh
Journal:
Acta Academiae Medicinae Sinicae
Year:
2009
Type:
Article